Aberrant p27kip1 expression in endocrine and other tumors.

Aberrant p27kip1 expression in endocrine and other tumors.
复制标题

DOI:
--
复制
发表时间:
1997-02
期刊:
The American journal of pathology
影响因子:
--
通讯作者:
Ricardo V. Lloyd;Long Jin;X. Qian;E. Kulig
Ricardo V. Lloyd;Long Jin;X. Qian;E. Kulig
中科院分区:
其他
文献类型:
--
作者:
Ricardo V. Lloyd;Long Jin;X. Qian;E. Kulig

文献摘要

被引文献

相似文献

p27 kip 1(p27)基因编码细胞周期蛋白依赖性激酶活性的抑制剂。采用免疫印迹法和免疫组化法检测p27蛋白在正常组织和肿瘤组织中的表达。免疫印迹研究检测到一个27-kd的蛋白带,与正常垂体相比,在肿瘤垂体组织中减少。177例组织的免疫组化结果显示,在正常组织中p27蛋白表达丰富,而在内分泌和非内分泌组织中腺瘤和癌中免疫反应阳性细胞数量减少。p27表达与用单克隆抗体MIB-1检测的增殖标记Ki-67抗原呈负相关。甲状旁腺腺瘤和增生有相似的Ki-67标记指数,然而,增生有三倍以上的p27阳性细胞比甲状旁腺腺瘤,这表明p27免疫染色可能是有用的,在区分这两种情况。这些结果表明,与正常组织相比,在增生组织和良恶性肿瘤中存在广泛的异常p27表达。p27沿着Ki-67的免疫组化分析可用于评估各种肿瘤的生物学行为,对增生性和肿瘤性组织进行分类,并研究肿瘤进展过程中的细胞周期调控。
The p27kip1 (p27) gene encodes an inhibitor of cyclin-dependent kinase activity. The expression of p27 protein in normal and neoplastic tissues was investigated by immunoblotting and immunohistochemistry. Immunoblotting studies detected a 27-kd protein band that was decreased in neoplastic pituitary tissues compared with normal pituitary. Immunostaining of 177 tissues showed abundant expression of p27 protein in normal tissues with decreased numbers of immunoreactive cells in adenomas and carcinomas in both endocrine and nonendocrine tissues. p27 expression was inversely related to the proliferation marker Ki-67 antigen detected with monoclonal antibody MIB-1. Parathyroid adenomas and hyperplasias had similar Ki-67 labeling indices; however, hyperplasias had threefold more p27-positive cells than parathyroid adenomas, suggesting that p27 immunostaining may be useful in distinguishing between these two conditions. These results indicate that there is widespread aberrant p27 expression in hyperplastic tissues and in benign and malignant neoplasms compared with normal tissues. Immunohistochemical analysis of p27 along with Ki-67 may be used to assess the biological behavior of various neoplasms, to classify hyperplastic and neoplastic tissues, and to study cell cycle regulation during tumor progression.